Physician profile
John Blankenship
NPI 1730160177
$9,205.53
in general payments reported to CMS, 2019-2025
52 companies · $1,316 in 2025
The $1,316 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $965 · 2020: $630 · 2021: $1,272 · 2022: $1,421 · 2023: $1,533 · 2024: $2,070 · 2025: $1,316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,824 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,824.25 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $870.80 | 2019-2025 | Xtandi, Veozah, Myrbetriq |
| Janssen Biotech, INC. | $816.80 | 2020-2025 | Erleada, Rybrevant, Carvykti |
| Bayer Healthcare Pharmaceuticals INC. | $770.70 | 2019-2025 | |
| Axonics, INC. | $638.46 | 2020-2024 | Bulkamid, Axonics |
| Teleflex LLC | $622.52 | 2021-2025 | Urolift, Barrigel |
| Pfizer INC. | $528.74 | 2019-2025 | |
| Abbvie INC. | $463.17 | 2019-2025 | Botox |
| Ferring Pharmaceuticals INC. | $421.23 | 2024-2025 | Adstiladrin |
| Sumitomo Pharma America, INC. | $387.19 | 2023-2025 | Orgovyx, Gemtesa |
| Dendreon Pharmaceuticals LLC | $375.88 | 2019-2025 | Provenge |
| Boston Scientific Corporation | $307.05 | 2019-2025 | Ams 700, General - Erectile Dysfunction, Axonics |
| Myriad Genetic Laboratories, INC. | $265.20 | 2020-2024 | Prolaris |
| Endo Pharmaceuticals INC. | $215.39 | 2019-2023 | Xiaflex |
| Blue Earth Diagnostics | $198.77 | 2019-2024 | |
| Myovant Sciences INC. | $194.55 | 2021-2022 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Blankenship listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.